LLY
Eli Lilly and Company
LLY has the edge over MDWD overall, supported by stronger fundamentals and stronger modeled upside.
MDWD
MediWound Ltd.
MDWD's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDWD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
MDWD's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MDWD PE Valuation
MDWD has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MDWD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MDWD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MDWD on earnings quality, reporting a profit while its opponent remains loss making.
MDWD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.60 | +$1.04 |
| Q1 2026 | -$2.26 | -$0.17 |
| Q4 2025 | -$2.10 | +$0.97 |
| Q3 2025 | -$1.90 | +$1.00 |
| Q2 2025 | -$2.64 | -$0.48 |
| Q1 2025 | -$2.09 | -$0.71 |
| Q4 2024 | -$3.07 | -$2.30 |
| Q3 2024 | -$2.90 | -$1.14 |
MDWD is still losing money, but far less than before: $1.60 per share over the past year, against $3.85 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MDWD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MDWD on profitability, with a higher operating margin.
MDWD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.1M | -46% |
| Q1 2026 | $1.5M | -63% |
| Q4 2025 | $1.9M | -68% |
| Q3 2025 | $5.4M | +25% |
| Q2 2025 | $5.7M | +13% |
| Q1 2025 | $4M | -20% |
| Q4 2024 | $5.8M | +9.4% |
| Q3 2024 | $4.4M | -8.8% |
MDWD's revenue has slid since its 2022 peak: $3M last quarter, down 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -306% | -206 points |
| Q1 2026 | -541% | -409 points |
| Q4 2025 | -418% | -314 points |
| Q3 2025 | -120% | -3.5 points |
| Q2 2025 | -100% | -12 points |
| Q1 2025 | -132% | -57 points |
| Q4 2024 | -104% | -31 points |
| Q3 2024 | -117% | -53 points |
MDWD's operating margin was −306% last quarter, down 206 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MDWD on cash generation, producing positive trailing cash flow while its opponent burns cash.
MDWD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10.1M | -$3.3M |
| Q1 2026 | -$8.6M | -$3.5M |
| Q4 2025 | -$5.5M | -$3M |
| Q3 2025 | -$4.3M | +$664K |
| Q2 2025 | -$6.8M | -$166K |
| Q1 2025 | -$5.1M | +$193K |
| Q4 2024 | -$2.4M | +$2.4M |
| Q3 2024 | -$4.9M | -$12K |
MDWD has burned cash in almost every quarter: −$28M over the past year, against −$19M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MDWD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MDWD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +9.8K shares |
| 1 year | +19% | +2M shares |
| 3 years | +40% | +3.7M shares |
| 5 years | +231% | +9M shares |
| Available history | +232% | +9M shares |
MDWD has 13M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $747,000 |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
MDWD spent $747,000 buying back its own shares over the past year, after none the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MDWD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -11.2x | Net Cash |
| Q4 2023 | -2.1x | Net Cash |
| Q1 2020 | -1.1x | Net Cash |
| Q4 2019 | -1.3x | Net Cash |
| Q3 2019 | -0.5x | Net Cash |
MDWD has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MDWD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 59.4 | Neutral |
MDWD's weekly RSI is 44 (neutral) and its Stochastic is 59 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MDWD PE vs Healthcare Sector
| Metric | MDWD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MDWD has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MDWD on trend strength, trading above more of its moving averages.
MDWD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.0 | 0.5% below |
| 20 week MA | $13.5 | 4.1% below |
| 50 week MA | $15.5 | 17% below |
| 100 week MA | $16.9 | 23% below |
| 200 week MA | $15.1 | 14% below |
MDWD is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MDWD on returns for 2026, with the stronger performance.
MDWD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.1 | $28.6 | +35% |
| 2021 | $28.6 | $15.8 | -45% |
| 2022 | $15.8 | $11.5 | -27% |
| 2023 | $11.5 | $10.2 | -12% |
| 2024 | $10.2 | $17.7 | +74% |
| 2025 | $17.7 | $18.8 | +6.2% |
| 2026 YTD | $18.8 | $13.0 | -31% |
MDWD has finished lower in three of the last six years. It's down 31% so far in 2026.